Cytoagents inc
WebCytoAgents is developing an innovative solution for the treatment of symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, … WebHeadquarters. CytoAgents, Inc 100 S. Commons Suite 102 Pittsburgh, PA 15212 (412) 303-1200 [email protected]
Cytoagents inc
Did you know?
WebFunding. CytoAgents has raised a total of $10.2M in funding over 9 rounds. Their latest funding was raised on Aug 11, 2024 from a Venture - Series Unknown round. CytoAgents is funded by 6 investors. Innovation Works and National Institutes of Health are the most recent investors. WebApr 28, 2024 · About CytoAgents CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, influenza, viral infectious ...
WebCytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms … WebAbout GENCO Systems. GENCO Systems, Inc. was established in 1994 to provide the Federal Government and industry with superior professional services in engineering and …
WebCytoAgents, Inc 1,122 followers 11h Report this post Report Report. Back ... WebSep 7, 2024 · PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer.Dr. …
http://gencosystems.com/about-gencosystems.html
WebSep 7, 2024 · PITTSBURGH-- ( BUSINESS WIRE )-- CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. lithocarpus philippinensisWebAug 10, 2024 · CytoAgents is a privately held, clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of … imsm companyWebNov 10, 2024 · September 07, 2024. CytoAgents Announces Appointment of New Chief Medical Officer. Addition of Arthur P. Bertolino Brings World Class Capabilities to Leadership Team, Positions CytoAgents for Phase 1b/2a Clinical Trials and Strategic Pharma Partnerships to Treat Cytokine Release Syndrome. Media Coverage. February 04, 2024. ims may schedule 2023WebNov 8, 2024 · CytoAgents, Inc. Teresa Whalen; CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products to treat life-threatening symptoms associated with cytokine release syndrome, an excessive immune response that causes overwhelming inflammation. CytoAgents’ team includes … ims mca feesWebCytoAgents has raised a total of $10.2M in funding over 9 rounds. Their latest funding was raised on Aug 11, 2024 from a Venture - Series Unknown round. CytoAgents is funded … litho cartonWebCytoAgents is a biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza, and other viral … imsm companies houseWebJun 20, 2024 · CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases. Where We Are 100 S … ims mba fees